HeartSciences Shareholders Approve Merger Proposal and Corporate Structure Changes
Key Facts
HeartSciences shareholders approved the merger agreement and related transactions at a special meeting held on 19 November 2026, with 3,480,989 shares voting in favor, 20,933 against and 3,150 abstaining, according to a company filing with the U.S. Securities and Exchange Commission. The company said in its filing that the meeting was convened to vote on the merger agreement and related proposals. A total of 4,041,647 shares were present or represented by proxy, equal to 76.36% of the shares eligible to vote. Voting eligibility was based on the shareholder record as of 8 October 2026, and the filing said a quorum was present. The approval is a step toward the transaction, but does not mean it has closed; closing conditions and listing requirements remain in place.
Shareholders also approved the Nasdaq proposal concerning the issuance of shares related to the transaction and potential additional issuances, with 3,459,400 shares voting in favor, 43,445 against and 2,228 abstaining. Subject to its terms, the proposal allows for the issuance of up to 35,000,000 Class A shares within one month of closing. The maximum aggregate consideration is $100,000,000, with a discount of no more than 20% to the market price. The authorization makes the number of additional shares and the terms of their issuance capital matters tied to the transaction's execution. Shareholders also approved an amendment and restatement of the existing equity incentive plan, with 3,207,036 shares voting in favor and 281,504 against.
The approved proposals included changing the company's proposed name to Fortitude Mining Group, Inc. Shareholders also authorized the board to effect a reverse stock split at a ratio to be determined by the board in agreement with Fortitude Seller, within a range of one share for every two shares to one share for every five shares. The vote does not make the split effective automatically, as it leaves the choice of ratio to the board and an agreement with the seller. These decisions are part of the proposals the company presented to shareholders alongside the merger agreement. Implementation of any measures tied to closing remains subject to the transaction's conditions and required procedures.
Under the announced agreement, HeartSciences and Fortitude Mining Holdings agreed to combine in an all-stock transaction. The combined company was expected to operate under the Fortitude brand, with its Class A shares trading under the symbol TUDE, subject to listing requirements and Nasdaq approval. Arrangements announced before the vote also provided for an “Up-C” structure after closing, with DCG expected to hold about 94% of the combined company's voting rights on a fully diluted basis. This means the proposed transaction would shift the group's business focus to Fortitude, with an expected change in name, ticker and ownership structure. These details remain contingent on closing the transaction and meeting its conditions.
Fortitude operates in digital asset mining, according to the company filing, through self-mining and owned data centers supported by long-term power contracts, with a focus on the Zcash network. Fortitude said it entered into two agreements in May 2026 to purchase 9,000 Antminer Z15 Pro machines, for a total value of $31.5 million. The company estimated that deploying the machines would add about 7.56 gigahashes per second to its mining capacity. In management arrangements, Jaime Leverton was appointed Fortitude's chief executive effective 21 September 2026 and was expected to remain in the role and on the board after the transaction closes. These disclosures provide a picture of the business around which the combined company would be centered if the transaction closes.
The vote comes as HeartSciences faces a compliance issue disclosed in an earlier filing: the company said Nasdaq notified it on 4 August 2026 that it did not meet the minimum stockholders' equity requirement. The company estimated stockholders' equity at about $0.2 million as of 30 April 2026, compared with a minimum of $2.5 million under the cited rule. The company said Nasdaq's confirmation that the shares would remain listed was a condition to closing the transaction. It also warned that failure to complete the transactions on the expected terms or within the expected timeframe could harm HeartSciences' business and cause its share price to decline. In trading, HSCS closed at $2.10 on 18 November, after closing at $2.06 on 17 November.